A glypican-3-derived peptide vaccine against hepatocellular carcinoma

Yu Sawada, Mayuko Sakai, Toshiaki Yoshikawa, Kazuya Ofuji, Tetsuya Nakatsura

Research output: Contribution to journalComment/debatepeer-review

19 Citations (Scopus)


The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.

Original languageEnglish
Pages (from-to)1448-1450
Number of pages3
Issue number8
Publication statusPublished - 2012
Externally publishedYes


  • Clinical trial
  • Cytotoxic T lymphocyte
  • Glypican-3
  • Hepatocellular carcinoma
  • Peptide vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'A glypican-3-derived peptide vaccine against hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this